ADIPOQ and diabetes mellitus: Although there were no statistically significant differences in the treatment groups compared to the diabetes control group for adiponectin and resistin, its level in LDAT and high-dose albendazole treatments (HDAT) groups were higher 209% and 161% than diabetes control group, respectively (p > 0.05).